receptors with respect to their ability to signal via both G protein-dependent and G protein-independent mechanisms, with a focus on the multifunctional protein β-arrestin.
Introduction
Beta-adrenergic receptors (β1AR and β2AR) and angiotensin II type 1A receptors (AT1aR) are seven transmembrane receptors (7TMRs) that are common therapeutic targets for the treatment of hypertension, renal disease and heart failure. Indeed, pharmacologic agents which target these receptors as antagonists (beta blockers and angiotensin receptor blockers) have reduced complications and improved survival in patients with elevated blood pressure, renal impairment and decreased cardiac function (Brenner et al., 2001; Dahlof et al., 2002; Hjalmarson et al., 2000; Packer et al., 2002) .
Although these agents were developed as classic antagonists for their respective receptors (to block deleterious effects of classic G protein signaling), the emerging concept of functional selectivity challenges the traditional paradigm of these receptors as simple on/off switches (Urban et al., 2007) (Kenakin, 2001; Kenakin, 2005) . Implicit in the traditional scheme of receptor function is the concept of linear efficacy, which is the notion that a given ligand is equally effective at stimulating or inhibiting all cellular responses regulated by a given receptor (traditional agonist or antagonist). In the case of G protein coupled receptors (GPCRs), this paradigm entails either complete or partial activation or inhibition of G protein activity. However, investigations over the past 15 years have demonstrated that a single ligand can activate multiple signaling pathways with differing efficacies, by inducing distinct conformational changes in the receptor (Kenakin, 2001) . For example, a classically defined antagonist for a GPCR may prevent G protein signaling by placing the receptor in a conformation that does not activate an associated G protein. However, the receptor conformation induced by this ligand may simultaneously permit signaling through another mechanism, unrelated to G protein M O L # 6 7 0 6 6 7 the evolving concept of functional selectivity, by emphasizing the capacity of the receptor to function with greater complexity than as a simple on-off switch. The GPCRs role in activating MAP kinase signaling was initially attributed to components of the G protein complex such as Gβγ subunits of the inhibitory Gi protein (Daaka et al., 1997; Luttrell et al., 1996; Zou et al., 1998) . The involvement of Gi led to the concept of "G protein switching" where both the β1AR and β2AR were found to be able to induce ERK signaling through a switch in the coupling from Gs proteins to Gi proteins (Daaka et al., 1997; Martin et al., 2004) . This "switching" was subsequently found to be dependent on phosphorylation of the β1AR and β2AR by protein kinase A (PKA) thus providing early insight into the important role of receptor phosphorylation in activation of multiple signaling events (Daaka et al., 1997; Martin et al., 2004) . These studies demonstrated that a mechanism previously shown to mediate uncoupling of the βAR from Gs (and decrease signaling) also serves to 'switch' coupling of this receptor from Gs to Gi and initiate a new set of signaling events (Daaka et al., 1997; Martin et al., 2004; Zhu et al., 2001 ).
β-arrestin mediated MAP kinase signaling
While G protein switching provided initial insight into GPCR mediated activation of the MAP kinase system, the discovery that β-arrestin could play a major role in ERK signaling provided further detail into both the complex nature of GPCR signaling, and the multifunctional roles of the β-arrestin molecule (Maudsley et al., 2000) . β-arrestin mediated ERK signaling has been shown for both βARs and the AT1aR with distinct kinetics and molecular consequences. For example, in cells overexpressing the AT1aR or M O L # 6 7 0 6 6 8 the β2AR, G protein activation through the ligand bound receptor leads to peak ERK activity within two to five minutes (Ahn et al., 2004; Shenoy et al., 2006) . In contrast, β -arrestin-mediated signaling following angiotensin II (Ang II) stimulation of AT1aR or isoproterenol stimulation of β2AR has a slower and more prolonged pattern of ERK activation (Ahn et al., 2004; Shenoy et al., 2006) (Figure 2 ). Furthermore, β-arrestin mediated signaling by the AT1aR promotes only cytoplasmic ERK localization while G protein mediated ERK activation results in both nuclear and cytoplasmic localization (Ahn et al., 2004; Gaborik et al., 2003; Tohgo et al., 2003) .
The previously described process of GRK phosphorylation of the receptor is a critical step in directing this alternative β-arrestin mediated pathway, and detailed investigations highlight the different roles of the various GRK isoforms (Violin et al., 2006) . Inhibition of GRK 5 or 6 using siRNA technology attenuates β-arrestin mediated ERK activation via the β1AR and AT1aR, while it remains unaffected (or may even increase) when siRNA is used to knockdown GRK 2 or 3 expression (Kim et al., 2008; Kim et al., 2005; Noma et al., 2007) . β-arrestin dependent ERK signaling is also augmented by the ligand-bound AT1aR or β2AR when GRK 5 or 6 are overexpressed in the cell (Kim et al., 2005; Shenoy et al., 2006) . Remarkably, the β-arrestin component of the ERK response is reciprocally diminished by GRK 2 overexpression (Kim et al., 2005; Shenoy et al., 2006) . Investigation of β-arrestin mediated signaling via the β1AR has not only confirmed findings with other receptors, but has also led to the discovery of EGFR transactivation as a mechanism for β-arrestin mediated ERK signaling (Noma et al., 2007) . Indeed, β1AR stimulated β-arrestin dependent ERK signaling requires GRK 5/6
and results in the extracellular release of membrane bound Heparin-Binding EGF-like M O L # 6 7 0 6 6 9 growth factor (HB-EGF) to transactivate EGFR (Noma et al., 2007) . Interestingly, a β-arrestin dependent mechanism for transactivation of EGFR by AT1aRs, has recently been reported after activation of endogenously expressed angiotensin receptors in vascular smooth muscle cells (Kim et al., 2009 ).
Ligand directed signaling at adrenergic and angiotensin receptors
As the pluridimensional efficacy of receptors in the β-adrenergic and angiotensin receptor signaling pathways has been dissected, interest has grown in the possibility of selectively activating the different pathways with currently available or novel ligands.
The functional selectivity of different ligands has been evaluated by screening a variety of compounds for the beta-adrenergic receptors. Baker et al. showed the agonist and inverse agonist (defined as a decrease in basal or constitutive activity after ligand binding) response to β2AR activation with a series of ligands using isoproterenol as a reference compound (Baker et al., 2003) . Despite a significant decrease in cAMP production (inverse agonist effect), certain ligands (in particular the traditional βAR antagonist propranolol) demonstrate increased CRE-mediated transcription and MAP kinase activation (Baker et al., 2003) . In a similar set of experiments involving stimulation of β1AR and β2AR with a variety of traditional antagonists, Galandrin et al.
identified complex "efficacy profiles" for both receptor types (Galandrin and Bouvier, 2006) . For the β1AR, carvedilol, bucindolol and labetolol activate both adenylyl cyclase and ERK pathways to varying degrees, with carvedilol having the greatest ERK signaling among traditional "β-blockers" (Galandrin and Bouvier, 2006) . For the β2AR, the same three agents demonstrate both cAMP and ERK activity but with variable efficacy.
M O L # 6 7 0 6 6 1 0
Although these initial screening studies did not directly evaluate the mechanism of ERK activation and role of β-arrestin as a critical signaling molecule in the activation of the ERK pathway, more recent investigations have examined the ability of ligands to recruit β-arrestin and activate ERK in a "β-arrestin-biased" fashion (Kim et al., 2008; Wisler et al., 2007) .
β-arrestin bias and ligand-directed signaling through GPCRs
Using fluorescence resonance energy transfer (FRET) to quantify the magnitude of β-arrestin recruitment to β2ARs, a number of traditional β2AR agonists were found to exhibit variable efficacies for β-arrestin recruitment to the receptor (Drake et al., 2008) .
By comparing the ratio of cyclic AMP (cAMP) generation to the rate and magnitude of β-arrestin recruitment to the β2AR, Drake et al. were able to calculate a ligand specific β-arrestin "bias factor" (Drake et al., 2008) . Based on this bias factor, three of the ligands, ethyl-norepinephrine, isoetharine and n-cyclopentylbutanephrine (CBP) show the greatest β-arrestin bias (figure 3). In a related study, a series of traditional βAR antagonists were also evaluated for relative G protein and β-arrestin mediated signaling (Wisler et al., 2007 ). Of 17 ligands tested, only carvedilol demonstrated a unique signaling profile of negative efficacy for Gs-dependent adenylyl cyclase activation, while still weakly promoting β-arrestin recruitment, internalization and activation of ERK signaling.
Carvedilol and alprenolol are also able to promote β1AR mediated EGFR transactivation that occurs through the recruitment and activation of β-arrestin as shown in both in cell culture and murine myocardium (Kim et al., 2008 ) (figure 4), suggesting that this could be a primary mechanism for β1AR ligand-induced ERK activation in the heart (Kim et al., 2008; Noma et al., 2007) . Although these data suggest that measuring different signaling events downstream of a single ligand-receptor interaction can give clues to the degree of selective activation, it is important to note that the optimal means for quantifying ligand-directed "bias" for a GPCR-ligand is undetermined but an active field of research in receptor pharmacology (Kenakin, 2005; Kenakin and Miller, 2010; Kenakin, 2009; Rajagopal et al., 2010) . A major challenge is the parallel activation of a signaling pathway by multiple upstream effectors and interpreting this signaling product as a readout for functional selectivity. An example is MAP kinase signaling which can be activated by G protein, Src activation and β-arrestin, although the relative contribution may be different based on the ligand used for activation. As the field moves forward, experimental evidence will have to show ligand specific efficacy profiles for multiple readouts including intermediate proteins upstream of an effector protein such as MAPkinase.
Conformational changes in GPCRs and ligand-directed signaling
Current concepts support the notion that ligands such as carvedilol can induce unique conformations within the βAR that decrease G protein coupling while promoting selective GRK phosphorylation and β-arrestin mediated signaling. In fact, ligandinduced changes in receptor conformation have been directly studied using a modified β2AR with fluorophores ligated to the c-terminus and to a cysteine residue in the sixth transmembrane region (Granier et al., 2007) . Using this reporter, the Kobilka group has shown that different ligands induce variable changes in receptor conformation involving the C terminus (Granier et al., 2007) . More specifically, ligands known to activate β-M O L # 6 7 0 6 6 1 2 arrestin mediated MAP kinase signaling (i.e. isoproternol and epinephrine) appear to induce a unique conformation at the proximal C terminal tail compared with ligands that do not mediate β-arrestin mediated signaling (Ghanouni et al., 2001; Granier et al., 2007) .
The AT1aR has also been shown to be subject to ligand directed signaling by using an analog of Ang II known as SII AngII (Wei et al., 2003) . SII is a synthetically generated compound that does not induce G protein activity when bound to the AT1aR, but maintains the capacity to recruit β-arrestin. Therefore, binding of SII to the receptor results in no G protein mediated protein kinase C (PKC) activation but a robust β-arrestin dependent ERK signaling response (Ahn et al., 2004; Wei et al., 2003) . In the heart, treatment with SII leads to ERK signal transduction and enhanced myocyte contractility , 2004) or an increase in transcriptional activity (Gaborik et al., 2003) .
While a naturally occurring or engineered β1AR mutant that displays similar activity has not yet been described, another β1AR mutant (GRK -β1AR) that has disrupted GRK phosphorylation sites and is therefore unable to recruit β-arrestin has proven useful in understanding β-arrestin mediated ERK signaling in the heart (Noma et al., 2007) . Indeed, transgenic mice overexpressing the β1AR mutant GRK -β1AR, which cannot transactivate EGFRs develop worse cardiac dysfunction and increased myocyte apoptosis in response to chronic catecholamine stimulation. In addition to implicating EGFR transactivation as a protective mechanism in the development of heart failure, this study emphasizes the importance of receptor-based functional selectivity in modifying disease states, and provides impetus for developing novel therapeutics that selectively activate antiapoptotic signaling.
Physiologic implications of biased agonists for the GPCRs
The discovery and development of biased agonists for the βARs and AT1aR seems possible given the encouraging data with "β-arrestin-biased" receptors and ligands described above. However, we are only at the preliminary stages of fully understanding the complex nature of β-arrestin as an adaptor protein for cellular signaling. In addition, it will be important to examine other non-β-arrestin, non-G protein mediated signaling pathways that are differentially influenced by GPCR ligands with respect to important physiological outcomes and adverse effect profiles. β-arrestin: a scaffold for functional selectivity in adrenergic and angiotensin signaling
In the preceding sections, we have described the complex interplay between receptor structure, ligand binding, receptor phosphorylation and conformational changes that underlie the functional selectivity of the β1AR, β2AR and AT1aR. In the model described above, selective changes in receptor conformation induced by GRK-specific phosphorylation lead to variable efficacy of β-arrestin recruitment to the receptor, and a resultant change in β-arrestin mediated signaling (Shukla et al., 2008) , 2007) . The conformations adopted by β-arrestin after phosphorylation of a given receptor (i.e. β1AR) by a specific GRK (i.e. GRK 5) have yet to be fully defined, but these may be key determinants in propagating non G protein mediated signaling via the GPCRs.
β-arrestin as a multifunctional regulator of GPCR signaling
There is mounting evidence that β-arrestin conformation is an important regulatory factor in determining the proteins that the molecule recruits. One such example is a recent study by Mangmool et al. which shows that activation of the β1AR induces a conformational change in β-arrestin that promotes a stable complex between β-arrestin, Ca 2+ /calmodulin kinase II (CaMKII), and the cAMP-dependent guaninenucleotide exchange factor (Epac) (Mangmool et al., 2010) . The association of β-arrestin with the β1AR stabilizes a β-arrestin-CaMKII-Epac complex and promotes CaMKII signaling (Mangmool et al., 2010) . Interestingly, this β-arrestin conformation and stable
complex are not formed after activation of the β2AR despite an equivalent amount of β-arrestin recruitment to both βARs. Moreover, by using βAR chimeras (i.e. β2AR with β1AR c-terminal tail), it was shown that the c-terminus of the β1AR contains structural elements that promote β-arrestin mediated CaMKII signaling (Mangmool et al., 2010) .
In this case β-arrestin provides a scaffold for CaMKII signaling by effectively bridging G protein signaling (cAMP activation of Epac) with CaMKII to promote this cascade after β1AR stimulation (figure 5).
The multifunctional roles of β-arrestin also appear to have impact beyond the level of the receptor. For example, using a mass-spectrometry based proteomics approach, Xiao and colleagues have discovered a multitude of proteins interacting with β-arrestin in the basal state and after stimulation of the AT1aR (Xiao et al., 2007) . Of the greater than 300 proteins found to interact with β-arrestin, proteins involved in cellular signaling such as kinases, phosphatases and nuclei c acid binding proteins are highly represented in the "β-arrestin interactome". This study underscores the pivotal role of β-arrestin in cellular physiology and future research will undoubtedly examine differences in the interactome upon activation of β-arrestin-biased receptors and ligands.
Polymorphic variation in adrenergic and angiotension receptors
As data continues to accumulate regarding the functional selectivity of the angiotensin and adrenergic receptors, interest has grown in the pluridimensional efficacy of naturally occurring human receptor mutants. Indeed, a better understanding the selectivity of these mutants for a particular signaling pathway could lead to unique functional selectivity profiles for different ligands, which could lead to differential drug , 1997; Spiering et al., 2000) . Only one small pilot study has demonstrated a beneficial interaction between the angiotensin receptor blocker (ARB) candesartan and this polymorphism (de Denus et al., 2008) . However, no rigorous in vitro or in vivo evaluation of these polymorphisms has included an assessment of G protein independent MAP kinase signaling.
Future challenges for defining functional selectivity of ligands
As progress is made utilizing the currently available data to develop and test biased ligands for the βARs and AT1aR, we anticipate a number of challenges in defining functional selectivity. As evidenced in the preceding sections and summarized in a recent article by Rajagopal et al. multiple assays have been used to define relative G protein and β-arrestin activation (Rajagopal et al., 2010) . While the development of biased ligands will certainly begin at the biochemical and cellular level, we must also work to define which assays will translate into physiological effects. Factors that may play a role in differences between experimental systems and animal/human subjects include ligand concentration, receptor expression level and the activity/expression of certain effector proteins (i.e. variable GRK isoform expression in target tissues).
Furthermore, it is important to remember that a single receptor-ligand combination can activate a downstream effector using multiple pathways, and activate ( 1 0 ) : ( 2 ) : 
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